NCT05891275 is a clinical trial in Geographic Atrophy, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT05891275?

NCT05891275 is sponsored by Boehringer Ingelheim.

What condition does NCT05891275 study?

NCT05891275 studies Geographic Atrophy.

Is NCT05891275 still recruiting?

NCT05891275 is currently completed. Last updated 1 May 2025.

Are results published for NCT05891275?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-01 · How we verify

NCT05891275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Completed Results posted Last updated 1 May 2025

What this trial tests

trial in Geographic Atrophy in 68,563 participants. Completed in 1 December 2023.

Timeline

31 May 2023

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Boehringer Ingelheim
Status	Completed
Study type	OBSERVATIONAL
Enrollment	68,563
Start date	31 May 2023
Primary completion	1 December 2023
Estimated completion	1 December 2023
Sites	1 location across United States

Conditions studied

Geographic Atrophy — all drugs for Geographic Atrophy →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

50 and older, any sex, with Geographic Atrophy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Visual Acuity (VA) in Participant's Study Eye Primary · From index date of GA diagnosis up to 5 years

Change in visual acuity (VA) in participant's study eye is reported. Study eye is defined as the first eye with the disease, and fellow eye, the participant's second eye. Change in VA was determined by calculating the difference between mean visual acuity (VA) readings at index diagnosis, and mean at another timepoint, assessed yearly for participants with valid VA readings at both timepoints.

Change in VA (Year 1)

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	-2.8	-3.0 – -2.6

Change in VA (Year 2)

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	-5.9	-6.2 – -5.6

Change in VA (Year 3)

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	-8.6	-9.0 – -8.2

Change in VA (Year 4)

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	-10.3	-10.9 – -9.8

Change in VA (Year 5)

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	-11.9	-12.6 – -11.2

Number of Participants Who Developed or Progressed to Age-related Macular Degeneration (wAMD) in the Study Eye Primary · From index date of GA diagnosis up to 5 years.

Number of participants who developed or progressed to age-related macular degeneration (wAMD) in the study eye is reported. The criteria used to determine progression through development to wAMD was identifying when ICD (International Classification of Diseases) codes for wAMD were present in the study eye.

Participants with wAMD in 1+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1866

Participants with wAMD in 2+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2271

Participants with wAMD in 3+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2191

Participants with wAMD in 4+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1764

Participants with wAMD in 5+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1247

Number of Participants Who Developed or Progressed to Geographic Atrophy (GA) in the Fellow Eye Primary · From index date of GA diagnosis up to 5 years.

Number of participants who developed or progressed to geographic atrophy (GA) in the fellow eye is reported. For patients diagnosed with GA at baseline, the development of GA in the fellow eye was closely monitored over time, with progress tracked for each year.

Participants with GA in fellow eye in 1+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1102

Participants with GA in fellow eye in 2+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1319

Participants with GA in fellow eye in 3+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1207

Participants with GA in fellow eye in 4+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	936

Participants with GA in fellow eye in 5+ years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	635

Change in Lesion Location for Participants With wAMD in Study Eye Primary · From index date of GA diagnosis up to 5 years

Change in lesion location from extrafoveal to subfoveal in participants who developed wAMD in study eye is reported. Lesion location was assessed at index diagnosis and at each year, then stratified by whether a patient developed wAMD in the 5 years post diagnosis. Changes in lesion were calculated as the difference in the number of participants with extrafoveal location at index diagnosis of the study eye, compared to the number of participants with extrafoveal lesion in the study eye at each year.

Participants with change of lesion location in Year 1

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	9

Participants with change of lesion location in Year 2

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	26

Participants with change of lesion location in Year 3

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	28

Participants with change of lesion location in Year 4

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	31

Participants with change of lesion location in Year 5

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	44

Change in Lesion Location for Participants With GA in Fellow Eye Primary · From index date of GA diagnosis up to 5 years

Change in lesion location from extrafoveal to subfoveal in participants who developed GA in fellow eye is reported. Lesion location was assessed at index diagnosis and at each year, then stratified by whether a patient developed GA in the 5 years post diagnosis. Changes in lesion were calculated as the difference in the number of participants with extrafoveal location at index diagnosis of the study eye, compared to the number of participants with extrafoveal lesion in the study eye at each year.

Participants with change of lesion location in Year 1

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	27

Participants with change of lesion location in Year 2

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	41

Participants with change of lesion location in Year 3

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	59

Participants with change of lesion location in Year 4

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	67

Participants with change of lesion location in Year 5

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	89

Occurrence of GA Over Study Period Primary · Number of yearly counts of GA from 2018 to 2013, by quarterly average.

Incidence and prevalence of GA over time is reported. This endpoint analyzed the yearly counts of newly diagnosed or prevalent cases to help in understanding the progression of the overall disease.

Total new diagnosis of GA patients by quarterly average in 2018

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2208

Total new diagnosis of GA patients by quarterly average in 2019

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2227

Total new diagnosis of GA patients by quarterly average in 2020

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1881

Total new diagnosis of GA patients by quarterly average in 2021

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2273

Total new diagnosis of GA patients by quarterly average in 2022

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2388

Total new diagnosis of GA patients by quarterly average in 2023

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	3307

Retinal Disease-related Outcomes: Number of Visits Per Quarter in a Year Secondary · Mean number of quarterly visits from 2019 up to 2023.

The retinal disease-related healthcare resource utilization (HCRU) outcome, number of visits by participants per quarter in a year is reported.

Mean number of visits in first quarter of 2019

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0.990	± 0.97

Mean number of visits in first quarter of 2020

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0.983	± 0.99

Mean number of visits in first quarter of 2021

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1.032	± 1.01

Mean number of visits in first quarter of 2022

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1.057	± 0.99

Mean number of visits in first quarter of 2023

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1.373	± 0.90

Retinal Disease-related Outcomes: Number of Anti-VEGF Injections Per Quarter Secondary · Mean number of quarterly anti-VEGF injections from 2019 up to 2023.

The retinal disease-related healthcare resource utilization (HCRU) outcome, number of anti-vascular endothelial growth factor (anti-VEGF) injections per quarter in a year is reported.

Mean number of anti-VEGF injections in first quarter of 2019

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0.233	± 0.63

Mean number of anti-VEGF injections in first quarter of 2020

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0.250	± 0.65

Mean number of anti-VEGF injections in first quarter of 2021

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0.275	± 0.68

Mean number of anti-VEGF injections in first quarter of 2022

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0.295	± 0.70

Mean number of anti-VEGF injections in first quarter of 2023

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0.442	± 0.82

Retinal Disease-related Outcomes: Number of Participants With Ocular Comorbidities by Year of Follow up Secondary · Total number of participants with ocular comorbidities were documented from index date up to 5 years.

The retinal disease-related HCRU outcome, number of ocular comorbidities by year of follow up is reported.

Participants with ocular comorbidities in study eye: on or before index

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	36518

Participants with ocular comorbidities in study eye: in the first year

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	38507

Participants with ocular comorbidities in study eye: in the first 2 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	39506

Participants with ocular comorbidities in study eye: in the first 3 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	40077

Participants with ocular comorbidities in study eye: in the first 4 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	40382

Participants with ocular comorbidities in study eye: in the first 5 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	40546

HCRU Outcome: Number of Participants With the Medical Procedure of Corneal Transplant Secondary · Total number of participants with corneal transplants were documented from index date up to 5 years.

The number of participants with corneal transplant during the observational period is reported.

Participants with corneal transplant in study eye: on or before index

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	6

Participants with corneal transplant in study eye: in the first year

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	7

Participants with corneal transplant in study eye: in the first 2 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	8

Participants with corneal transplant in study eye: In the first 3 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	10

Participants with corneal transplant in study eye: in the first 4 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	11

Participants with corneal transplant in study eye: in the first 5 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	11

HCRU Outcome: Number of Participants With the Medical Procedure of Incisional Glaucoma Surgery Secondary · Total number of participants with incisional glaucoma surgery were documented from index date up to 5 years.

Number of participants with incisional glaucoma surgery during the observational period is reported.

Participants with incisional glaucoma surgery in study eye: on or before index

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0

Participants with incisional glaucoma surgery in study eye: in the first year

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0

Participants with incisional glaucoma surgery in study eye: in the first 2 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0

Participants with incisional glaucoma surgery in study eye: in the first 3 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0

Participants with incisional glaucoma surgery in study eye: in the first 4 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0

Participants with incisional glaucoma surgery in study eye: in the first 5 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	0

HCRU Outcome: Number of Participants With the Medical Procedure of Vitrectomy Secondary · Total number of participants with vitrectomy were documented from index date up to 5 years.

Number of participants with vitrectomy during the observational period is reported.

Participants with vitrectomy performed on study eye: on or before index

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1579

Participants with vitrectomy performed on study eye: in the first year

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1858

Participants with vitrectomy performed on study eye: in the first 2 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1955

Participants with vitrectomy performed on study eye: in the first 3 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	1995

Participants with vitrectomy performed on study eye: in the first 4 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2038

Participants with vitrectomy performed on study eye: in the first 5 years

Group	Value	95% CI
Patients With Geographic Atrophy (GA)	2062

Sponsor's own description

To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Geographic Atrophy

Currently open trials in the same condition.

NCT07215234 — A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Se · Phase 1, PHASE2 · recruiting
NCT06961370 — A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO76693 · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06769048 — A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) C · Phase 2 · active not recruiting
NCT06805474 — A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05891275 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 1 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05891275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing